CYTEK BIOSCIENCES, INC.
Last · NASDAQ$5.395+0.045 (+0.84%)close · yahoo · 16h ago
Market cap$701.26M130.0M sh
P/E · TTM-8.7fwd 77.1 · eps -0.62 · loss
Beta1.16vs S&P 500
Div yield0.00%annual · TTM
52w range
$3.31$6.21
Volume1.1Msession
| Revenue | $201.5M |
|---|---|
| Operating income | $-40.4M |
| Net income | $-66.5M |
| Free cash flow | $-8.8M |
| Operating margin | -20.0% |
| Net margin | -33.0% |
| Return on equity | -19.5% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-26
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -33.0%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -2.3%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
$0.03
Est. revenue
52.9M
Earnings transcripts
Press & signals
- GlobeNewswire
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
- GlobeNewswire
Cytek Biosciences Reports Second Quarter 2026 Financial Results
Documents
FormReporting forFiledFlags